Skip to main content

Cardiovascular Risk Reduction News (Page 19)

FDA Approves Expanded Indication for Brilinta to Include Long-Term Use in Patients with a History of Heart Attack

Thursday, 3 September 2015 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Brilinta (ticagrelor) tablets at a new 60mg dose to be used in patients with a...

FDA Approves Entresto (sacubitril/valsartan) for Heart Failure

July 7, 2015 – The U.S. Food and Drug Administration today approved Entresto (sacubitril/valsartan) tablets for the treatment of heart failure. The drug has been shown to reduce the rate of...

FDA Approves Zontivity to Reduce the Risk of Heart Attacks and Stroke

May 8, 2014 – The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore...

FDA Medwatch Alert: Enteric Coated Aspirin 81 mg Tablets by Advance Pharmaceutical Inc.: Recall of One Lot - May Contain Acetaminophen 500 mg Tablets

ISSUE: Advance Pharmaceutical Inc. announced that this firm is conducting a voluntary nationwide recall to the user level of the over-the-counter drug product, Rugby label Enteric Coated Aspirin...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Prevention of Cardiovascular Disease

Related drug support groups

Xarelto, Ozempic, Victoza, simvastatin, Wegovy, semaglutide, Repatha, Trulicity, Brilinta, view more... Jardiance, ramipril, liraglutide, dulaglutide, Invokana, rivaroxaban, ticagrelor